1. Patients contraindicated or with history/ evidence of hypersensitivity to Tocilizumab or any of the components of formulation. <br/ >2. Patients requiring intubation and mechanical ventilation <br/ >3. Patients with ALT/AST â?¥ 5 x upper limit of normal (ULN) <br/ >4. Patients with platelet counts <1,00,000/cmm or absolute neutrophil counts <2000/cmm <br/ >5. Patients received oral anti-rejection or immunomodulatory drugs (including tocilizumab) within the past 3 months <br/ >6. Patients of immunocompromised status or on immunosuppressive therapy (except for steroids for COVID only), advanced cancer <br/ >7. Evidence of multiorgan failure <br/ >8. Treatment with an investigational drug within 5 half-lives or 30 days (whichever is longer) of randomization <br/ >9. Where, in the opinion of the investigator, participation in this study will not be in the best interest of the subject, or any other circumstances that prevent the subject from participating in the study safely <br/ >

1. Patients contraindicated or with history/ evidence of hypersensitivity to Tocilizumab or any of the components of formulation. <br/ >2. Patients requiring intubation and mechanical ventilation <br/ >3. Patients with ALT/AST â?¥ 5 x upper limit of normal (ULN) <br/ >4. Patients with platelet counts <1,00,000/cmm or absolute neutrophil counts <2000/cmm <br/ >5. Patients received oral anti-rejection or immunomodulatory drugs (including tocilizumab) within the past 3 months <br/ >6. Patients of immunocompromised status or on immunosuppressive therapy (except for steroids for COVID only), advanced cancer <br/ >7. Evidence of multiorgan failure <br/ >8. Treatment with an investigational drug within 5 half-lives or 30 days (whichever is longer) of randomization <br/ >9. Where, in the opinion of the investigator, participation in this study will not be in the best interest of the subject, or any other circumstances that prevent the subject from participating in the study safely <br/ >

N/A

N/A

1. Patients contraindicated or with history/ evidence of hypersensitivity to Tocilizumab or any of the components of formulation. <br/ >2. Patients requiring intubation and mechanical ventilation <br/ >3. Patients with ALT/AST â?¥ 5 x upper limit of normal (ULN) <br/ >4. Patients with platelet counts <1,00,000/cmm or absolute neutrophil counts <2000/cmm <br/ >5. Patients received oral anti-rejection or immunomodulatory drugs (including tocilizumab) within the past 3 months <br/ >6. Patients of immunocompromised status or on immunosuppressive therapy (except for steroids for COVID only), advanced cancer <br/ >7. Evidence of multiorgan failure <br/ >8. Treatment with an investigational drug within 5 half-lives or 30 days (whichever is longer) of randomization <br/ >9. Where, in the opinion of the investigator, participation in this study will not be in the best interest of the subject, or any other circumstances that prevent the subject from participating in the study safely <br/ >

1. Patients contraindicated or with history/ evidence of hypersensitivity to Tocilizumab or any of the components of formulation. <br/ >2. Patients requiring intubation and mechanical ventilation <br/ >3. Patients with ALT/AST â?¥ 5 x upper limit of normal (ULN) <br/ >4. Patients with platelet counts <1,00,000/cmm or absolute neutrophil counts <2000/cmm <br/ >5. Patients received oral anti-rejection or immunomodulatory drugs (including tocilizumab) within the past 3 months <br/ >6. Patients of immunocompromised status or on immunosuppressive therapy (except for steroids for COVID only), advanced cancer <br/ >7. Evidence of multiorgan failure <br/ >8. Treatment with an investigational drug within 5 half-lives or 30 days (whichever is longer) of randomization <br/ >9. Where, in the opinion of the investigator, participation in this study will not be in the best interest of the subject, or any other circumstances that prevent the subject from participating in the study safely <br/ >